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Abstract: Low-dose tablet formulations were produced with excellent homogeneity based on
drug-loaded electrospun fibers prepared by single-needle as well as scaled-up electrospinning
(SNES and HSES). Carvedilol (CAR), a BCS II class compound, served as the model drug while
poly (vinylpyrrolidone-co-vinyl acetate) (PVPVA64) was adopted as the fiber-forming polymer.
Scanning electron microscopy (SEM) imaging was used to study the morphology of HSES and SNES
samples. Different homogenization techniques were compared to maximize homogeneity: mixing
in plastic bags and in a high-shear granulator resulting in low-shear mixing (LSM) and high-shear
mixing (HSM). Drug content and homogeneity of the tablets were measured by UV-Vis spectrometry,
the results revealed acceptably low-dose fluctuations especially with formulations homogenized with
HSM. Sieve analysis was used on the final LSM and HSM powder mixtures in order to elucidate the
observed differences between tablet homogeneity. Tablets containing drug-loaded electrospun fibers
were also studied by Raman mapping demonstrating evenly distributed CAR within the corpus.
Keywords: carvedilol; poly (vinylpyrrolidone-co-vinyl acetate); high-speed electrospinning;
high-shear mixing; homogenization; Raman mapping; sieve analysis
1. Introduction
Tablets are generally regarded as the most popular and accepted dosage forms in pharmaceutical
technology. Their ease of manufacturing and high patient compliance make them an ideal choice for both
the industry and therapeutics [1]. Tablets are available with doses ranging from very low (micrograms)
to very high (1–2 g). In such extreme cases, manufacturing becomes more challenging which is especially
true for microgram dosed formulations. Handling low quantities of active pharmaceutical ingredients
(APIs) can often lead to decreased drug content and high relative standard deviation (RSD) values in
the final batches [2]. Proper content uniformity (CU) among others is one of the basic requirements of
tablets by Pharmacopeias across the world [3] ensuring high quality and patient safety.
In terms of formulation development, amorphous solid dispersions (ASD) are getting more recognition
since enhanced dissolution and bioavailability can be achieved this way [4]. Techniques capable of
manufacturing ASDs on the industrial scale, such as spray drying (SD) [5] and hot-melt extrusion (HME) [6]
have already produced FDA approved formulations such as Raplixa [7] and NuvaRing [8]. However, SD
generally requires high capital investment for the equipment and its maintenance, while it has a low thermal
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efficiency due to the large volume of hot air circulating in the drying chamber [9]. HME usually operates
at even higher temperatures that should be avoided in case of thermosensitive components and it is not
applicable for ASD formation in case of APIs of very high melting points [10].
On the other hand, both SD and HME are continuous technologies, which are heavily encouraged
by the leading regulatory agencies [11]. Continuous manufacturing has multiple advantages
over traditional batch methods, such as huge improvement in productivity, time-efficiency, less
energy requirement and a reduced amount of actual waste [12]. As of today, three products
have been produced and approved this way in the following chronological order: Orkambi
(lumacaftor/ivacaftor) manufactured by Vertex [13], Prezista (darunavir) produced by Janssen [14]
and Symdeko (tezacaftor/ivacaftor and ivacaftor) also developed by Vertex [15].
Electrospinning (ES) is a unique method enabling the production of ASDs from a polymer solution
or melt [16,17]. Applying ES polymer fibers are formed in the micro and nanometer scale by the creation
and elongation of an electrified fluid jet [18]. In comparison with the aforementioned ASD producing
technologies, ES operates at ambient conditions resulting in a gentle drying process at minimal costs [19].
The electrospun fibers have an enormous surface area where the API is often molecularly dispersed
in a polymer matrix, producing a nano-amorphous solid dispersion (NASD) [20–23]. ES is also being
investigated for various biomedical purposes for its advantages in controlled delivery [24–27], tissue
engineering [28,29], wound dressing, enzyme immobilization and biodrug delivery [30].
Regarding scaled-up nanofiber production, the high-speed electrospinning (HSES) technology has
the capability to produce approximately half kg of product per hour [31] in accordance with industrial
guidelines, while the traditional single-needle electrospinning (SNES) technique can only produce a
few grams per hour at best [32,33]. HSES achieves this increased output by combining electrostatic and
high-speed rotational jet generation [34,35]. There are also other alternate methods such as pressurized
gyration [36], infusion gyration [37] and pressure-coupled infusion gyration [38], that have shown the
capability of increased nanofiber output. The latest results and their possible future implications are
assembled in a most recent review article [39].
The tableting of electrospun nanofibrous materials is a rather new concept so only a few studies
have been reported that tackle this field [40–42]. However, there is no publication dealing with the
homogeneity challenges in tablet formulation. Based on our previous experiences, this can be mainly
attributed to the flowability concerns during downstream processing of the ES material. Moreover,
ensuring homogeneity, and thus, appropriate CU can be a tall order when very low doses are needed
especially in the case of tablets based on electrospun fibers [43].
To produce ES-based tablets on the industrial scale at any dose, the homogenization characteristics
need to be better comprehended and implemented. This work aimed at developing a suitable
technology to provide low-dose tablets with proper homogeneity containing electrospun substance
prepared by an industrial HSES process. For this purpose, a direct compression (DC) technology was
intended to be applied along with industrial tableting by a tablet rotary press. A model system was
selected containing carvedilol (CAR, Figure 1), an antihypertensive drug, and PVPVA64, a copolymer
as the matrix forming agent (the model drug was selected for analytical reasons, not for any biological
relevance at such a low concentration).
Figure 1. Carvedilol.
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2. Materials and Methods
2.1. Materials
Carvedilol (CAR) was provided by Sigma-Aldrich (Budapest, Hungary) with purity ≥ 98%
and a melting point of 117 ◦C. Kollidon VA 64 (Copovidone, PVPVA64) was supplied by BASF
(Ludwigshafen, Germany), is a vinylpyrrolidone/vinylacetate amorphous copolymer (6:4) with
a molecular weight in the range of 45–70 kDa. Lactose monohydrate (Flowlac 100 mesh) was
provided by Meggle Pharma (Wasserburg, Germany), while microcrystalline cellulose (Vivapur 112),
Croscarmellose sodium (Vivasol) and sodium stearyl fumarate (Pruv) were supplied by JRS Pharma
(Rosenberg, Germany).
2.2. Single-Needle Electrospinning (SNES)
The single-needle electrospinning experiments were carried out using a spinneret equipped with
an NT-35 high voltage DC supply (Unitronik Ltd., Nagykanizsa, Hungary). An electric potential of
25 kV was applied to the spinneret electrode. Sample collection was obtained using a grounded
aluminum plate completely covered by aluminum foil. The distance of the spinneret from the
collector was set at 15 cm, and the experiments were executed at ambient temperature (25 ◦C).
The electrospinnable solution (Table 1) was dosed utilizing a SEP-10S Plus type syringe pump (Aitecs,
Vilnius, Lithuania). The feed rate was 6 mL/h.
Table 1. Tablet composition.
Applied Tableting Ingredients Amount (mg)/Tablet Amount (%)/Tablet
Total Amount of
Materials
(Batch Size 5000 Tablets)
Electrospun/Crys. Carvedilol 0.05 0.05 0.25 g
poly (vinylpyrrolidone-co-vinyl acetate)
(PVPVA64) 4.95 4.95 24.75 g
Flowlac 100 mesh (amorphous lactose) 65.00 65.00 325 g
Microcrystalline cellulose (MCC) 112 25.50 25.50 127.5 g
Croscarmellose sodium (CCS) 3.00 3.00 15.0 g
Sodium stearyl fumarate (Pruv) 1.5 1.50 7.5 g
∑ 100.0 100.0 500.00 g
2.3. High-Speed Electrospinning (HSES)
The scaled-up electrospinning productions were achieved by adopting a high-speed electrostatic
spinning setup made up of a stainless steel spinneret with sharp edges and spherical cap geometry
controlled by a high-speed motor. The electrospinnable solution was dosed by means of a SEP-10S
Plus syringe pump. The flow rate was set at 750 mL/h. A rotational speed of 35,000 rpm was applied
to the spinneret, while the voltage was 35 kV through the experiments (NT-65 high voltage DC supply
Unitronik Ltd., Nagykanizsa, Hungary). The grounded collector completely covered by aluminum foil
was positioned 35 cm from the spinneret in each case. The manufacture of fibers was carried out at
ambient temperature (25 ◦C). More details about HSES can be found in the literature [44].
2.4. Low-Shear and High-Shear Homogenization
Homogenizations were carried out in plastic bags (low-shear mixing, LSM) or in a Diosna P-06
high-shear mixer (HSM). The tablet composition is detailed in Table 1.
A 100-mesh amorphous lactose called Flowlac was used as the filler, microcrystalline cellulose
type 112 was applied as the binder, croscarmellose sodium (CCS) was adopted as the superdisintegrant
and sodium stearyl fumarate (SSF) was implemented as the lubricant.
In the HSM setup, the chopper blades are set horizontally, which is standard for Diosna
high-shear mixers.
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In practice, all ingredients except the API and SSF were placed into plastic bags (LSM) or into
the HSM, where they were pre-homogenized in 2 min (200 rpm impeller, 600 rpm chopper for
HSM). Then the electrospun product or the crystalline CAR was added to the mixture, where it was
homogenized in 7 min (200 rpm impeller, 850 rpm chopper for HSM). Upon completion, the mixtures
were sieved applying a 500 µm sieve. Finally, SSF was added and blended with the other components
in 30 s (200 rpm impeller, 0 rpm chopper for HSM).
2.5. Tableting and in Process Control (IPC) Tests
The average tablet weight was set to 100 mg, with the dose of CAR at 50 µg. Tableting was
performed on a Riva Piccola tablet rotary press machine using 8 tablet dies with 6 mm diameter and
no markings. Table speed was 40 rpm, Fill-O-Matic was 7 rpm and compression force was between
1–1.5 kN. A reference batch was also produced containing crystalline carvedilol as the API. Each batch
consisted of 5000 tablets.
The compressed tablets were evaluated by IPC tests, such as tablet weight, thickness, hardness,
friability measurement and time of disintegration. The first 3 were determined by an Erweka
MultiCheck apparatus, while friability tests were conducted in a Pharmatest PTFR-A analyzer and
disintegration time was measured in a Pharmatest PTZ-Auto disintegration tester. All in all 10 tablets
were examined by the MultiCheck, 6 tablets were studied by the PTZ-Auto and tablets with the
sum weight of 6.5 g were evaluated by the PTFR-A. Friability tests were made according to the
Pharmacopeias with 100 turns in 4 min [45].
2.6. Scanning Electron Microscopy (SEM) and Fiber Diameter Analysis
Sample morphology was studied by applying a JEOL 6380LVa (JEOL, Tokyo, Japan) type scanning
electron microscope. Initially, the samples were secured by virtue of a conductive double-sided carbon
adhesive tape, then were coated with an alloy consisting of gold-palladium prior to investigation.
The applied accelerating voltage was between 15 and 25 kV, while the working distance was in the
range of 12–16 mm. A randomized fiber diameter determination method developed in-house was
implemented as described in our previous work [46], n = 100 measurements were made on each sample.
2.7. Differential Scanning Calorimetry (DSC)
The differential scanning calorimetry (DSC) experiments were made with a DSC 92 Setaram
device (Caluire, France). The average sample weight of ~10–15 mg was placed in a closed aluminum
pan. A nitrogen purge gas flow of 50 mL/min was used in all experiments. The temperature program
started with a preliminary isothermal period that lasted for 1 min at 25 ◦C. Upon completion, a
subsequent linear heating phase ensued from 25 ◦C to 200 ◦C at a rate of 10 ◦C/min. Purified indium
standard was applied for calibration.
2.8. Raman Mapping
Raman mapping was performed using Horiba Jobin-Yvon LabRAM-type microspectrometer with
external 785 nm diode laser source and Olympus BX-40 optical microscope. The laser beam was
focused by an objective of 20 × (NA = 0.4) to the tablet surface. The confocal hole of 1000 µm was
used in the confocal system. 950 groove/mm grating monochromator dispersed the backscattered
light. The spectral range of 460–1680 cm−1 was detected as the relevant range with 5 cm−1 resolution.
Spectral data were collected from 41 × 41 points with 25 µm step size. The acquisition time was
40 s and two spectra were averaged per point. The classical least squares (CLS) method was applied
to calculate the concentration of the different materials. All reference spectra (excipients and ES
samples) were recorded and the combination of these was used to approximate the spectra of the maps.
The so-obtained coefficients were depicted in the maps.
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2.9. Content Uniformity Analysis
Content uniformity (CU) was measured by UV-Vis spectrometry. Ten random tablets were
individually put into 10 mL volumetric flasks where they were disintegrated in an acidic buffer
(pH 1) within an ultrasonic bath in 15 min. Upon completion they were filtered by a 0.45 µm
polytetrafluoroethylene (PTFE) syringe filter and the concentration of CAR in the acidic buffer (pH 1)
was determined by a Hewlett-Packard HP 8453G UV-Vis spectrophotometer (Palo Alto, CA, USA) at a
wavelength of 241 nm based on a former calibration.
2.10. Sieve Analysis
Sieve analyses were made on the pure ES material and the final powder mixtures by a Fritsch
Analysette 3 Pro Vibratory Sieve Shaker (Idar-Oberstein, Germany). A total weight of 25 g was
investigated in each case. The pure ES material and the final powder mixtures were sieved for 10 min
with the amplitude set at 0.5. Upon completion, the sieved fractions were weighed and evaluated.
3. Results and Discussion
As briefly mentioned at the beginning of this paper, the goal was to achieve highly homogenous
NASD containing tablets with low doses of API. By doing so, we could develop a standard method
for producing high-quality electrospun products, which meet the requirements of the Pharmacopeias.
Fiber morphology of the HSES fibers was studied and compared with SNES samples by SEM. CU was
evaluated by UV-Vis spectrometry, while API distribution in the tablets was also studied with Raman
mapping and final powder mixture homogeneity was evaluated by sieve analysis.
3.1. Electrospinning
The preparation of the ES samples is detailed in Table 2.
Table 2. Comparison of the details of manufacturing using SNES and HSES.
Sample PreparationMethod
Applied
Solvent
Dissolved PVPVA64
and CAR (99:1) in
10 mL of Solvent (g)
Flow Rate
(mL/h)
Productivity
for Dried
Material (g/h)
PVPVA64 +1%
CAR SNES
Single-needle
electrospinning 96% EtOH 4.00 6 1.8
PVPVA64 +1%
CAR HSES
High-speed
electrospinning 96% EtOH 4.00 750 225
Single-needle electrospinning (SNES) is the basic method for preparing NASD; however, its
production rate (few grams of product an hour) is way too limited for industrial purposes and
applications. Our results fell in line with these assessments since our fiber production with SNES was
only 1.8 g per hour. On the other hand, HSES offered a much higher output rate resulting in 225 g of
fiber production per hour. In both cases, 96% ethanol was adopted as the solvent since it is accepted by
the Pharmacopeia. Using this new technology, it was possible to increase our productivity 125-fold in
regard to the dried product. It is encouraging that the output could have been further increased, but in
this case, it was only a secondary objective.
3.2. Fiber Morphology
Once the ES materials were obtained their morphology were investigated with SEM. The images
are shown in Figure 2. Upon inspecting them the average diameter was 1.02 ± 1.00 µm and
0.80 ± 0.31 µm for the HSES and SNES samples, respectively. However, the HSES sample contained
more beads indicating that further research is required to reach optimal morphology. This outcome
is likely the result of the fiber-forming technology. No crystalline objects were visible in either case,
suggesting their amorphous states.
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Figure 2. Scanning electron microscopic images of PVPVA64 + 1% CAR fibers prepared by high-speed
electrospinning (a) and single-needle electrospinning (b).
3.3. Differential Scanning Calorimetry
To examine the physical state of carvedilol in the electrospun samples, differential scanning
calorimetry measurements were carried out. Physical mixture and pure polymer were used
as reference.
The DSC curves are detailed in Figure 3.
Figure 3. (a,b) Differential scanning calorimetry (DSC) thermograms of PVPVA64, PVPVA64 + 1%
CAR physical mixture and fibers prepared by single-needle and high-speed electrospinning.
According to the thermograms, no endotherm melting peaks of API origin were observable in the
electrospun fibers and only a very slight curvature was detected at 120 degrees Celsius in the physical
mixture (3.b). Based on these results, we can assume that this faint signal comes from the minimal
amount of crystalline carvedilol melting in the aforementioned sample.
These data further indicate that total amorphization was achieved in both the scaled up (HSES)
and regular (SNES) ES samples. The wide endotherm peaks at lower temperatures are related to
water evaporation.
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3.4. Tableting
Once the ES products proved to be amorphous, a direct compression (DC) technology was
developed to compress them. DC technology is the safest, easiest and most economical way to
produce tablets since it takes the least amount of toll on the ingredients through simple and short
homogenization steps [47].
However, in order to successfully apply the technology, proper tableting materials are needed.
For our purposes, as they are briefly summarized in Table 1, an amorphous lactose with exceptional
flowability called Flowlac was co-processed with microcrystalline cellulose (with low water content
< 1.5%). The application of this MCC subtype was preferable since ES products are hygroscopic.
The adoption of both materials was desirable since (as it was described in our previous work [48]) the
electrospun samples can adhere to their surfaces. Ultimately, this phenomenon sets the foundation to
achieve proper homogenization.
Croscarmellose sodium, specifically developed for manufacturing tablets was used as the
superdisintegrant. These agents provide superior disintegration properties compared to regular
disintegrants while maintaining a low-dose (1–4%) in the formulation [49]. Lastly, Sodium stearyl
fumarate (Pruv), was adopted to lubricate the tablets. It is a hydrophilic agent, that has advantages
compared to magnesium stearate such as less sensitivity to over-lubrication [50].
For the DC technology only plastic bags, a high-shear mixer, and a tablet rotary press were
required. Only the HSES samples were compressed into tablets since the production of sufficient
amounts of ingredients by SNES would have taken days to fabricate. Overall, 6 batches were produced
4 of which contained ES product. Two were manually homogenized in plastic bags emulating industrial
container homogenization and the other two were homogenized in an HSM. The final two batches
contained crystalline carvedilol serving as reference. One was homogenized in LSM conditions and
the other by HSM. The batch characteristics are detailed in Table 3.
Table 3. Batch characteristics and their IPC results (A and B are repetitions of the same technology).
Characteristics LSMReference
HSM
Reference
LSM HSES
Batch A
LSM HSES
Batch B
HSM HSES
Batch A
HSM HSES
Batch B
API type CrystallineCAR
Crystalline
CAR
Electrospun
CAR
Electrospun
CAR
Electrospun
CAR
Electrospun
CAR
Method of
homogenization
Manual
(LSM)
High-shear
(HSM)
Manual
(LSM)
Manual
(LSM)
High-shear
(HSM)
High-shear
(HSM)
Weight (mg) 99.9 ± 0.5 99.2 ± 0.7 99.2 ± 0.8 100.2 ± 0.7 100.9 ± 1.0 99.8 ± 1.1
Thickness (mm) 3.08 ± 0.44 3.02 ± 0.54 3.06 ± 0.69 3.04 ± 0.57 3.05 ± 0.60 3.03 ± 0.52
Hardness (N) 64.3 ± 7.62 69.2 ± 6.22 60.6 ± 5.67 63.8 ± 7.51 68.6 ± 5.11 62.7 ± 6.71
Diameter (mm) 5.97 ± 0.19 5.95 ± 0.22 5.97 ± 0.27 5.98 ± 0.17 5.99 ± 0.29 5.97 ± 0.21
Friability (%) 0.21 0.31 0.39 0.25 0.20 0.27
Disintegration (s) 84 95 103 119 138 125
The HSM suitable for executing multiple technological steps, such as homogenization, granulation,
and drying, was expected to work well with the ES product [51]. Once the homogenizations were
completed, the mixtures were compressed into tablets using a tablet rotary press without any problems.
IPC tests were carried out to evaluate the oral dosage forms. The summary of the results is detailed in
Table 3.
According to the IPC results, all batches had roughly the same properties without any
unacceptable data. Friability was well below the 1% limit, while disintegration [52] was easily achieved
within 30 min both criteria set by the Pharmacopeias.
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3.5. Content Uniformity
The measured average API contents and their homogeneity are detailed in Table 4. The batches
containing crystalline carvedilol yielded expected results with acceptable API content and high RSD
values. These results can be linked to the low quantity of API (250 mg) applied and to the fact that
the average particle size of crystalline carvedilol is quite large, that makes its proper homogenization
quite difficult in such a small dose. This phenomenon could not be solved even in the HSM since
SD and RSD values were still too high, 4.65 and 5.13 respectively. Out of the ES samples, the batches
homogenized in HSM proved to be much better than the LSM tablets homogenized in plastic bags
under low-shear conditions. To differentiate between the samples, additional measurements were
carried out.
Table 4. UV-Vis results.
Sample
Number
Carvedilol %
LSM
Reference
HSM
Reference LSM ES A LSM ES B HSM ES A HSM ES B
Average 98.76 97.68 94.19 93.21 97.63 96.71
SD (%) 7.43 4.65 9.50 6.80 2.04 2.49
RSD 7.52 5.13 10.08 7.30 2.09 2.58
3.6. Raman Mapping Results
To evaluate the homogeneity differences between LSM and HSM ES tablets, Raman maps were
taken of the aforementioned solid dosage forms. Raman mapping is a non-destructive analytical
method enabling API homogeneity measurements in pharmaceuticals [53]. Analyses were conducted
on individual tablet surfaces, one from each batch.
Since directly searching for the API at such a low-dose (50 µg) with Raman spectrometry is a very
challenging task, an indirect method was applied. Given the fact, that the API is molecularly dispersed
in the PVPVA64 polymer matrix [54], we can assume that the homogeneity of the API is related to the
homogeneity of the polymer. Consequently, the maps were taken accordingly. These results are shown
in Figure 4.
Figure 4. Raman maps of LSM (a) and HSM (b) ES tablets (colorful images show the distribution of the
PVPVA64 polymer).
Upon inspecting the maps, the distribution of API could be indirectly investigated, but only slight
differences were detected within the standalone tablets. This result indicates, that the API containing
polymer is evenly distributed in the single solid dosage forms. However, this still does not explain the
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large inhomogeneity deviations discovered by the CU measurement, which is a result of evaluating
multiple tablets at once.
3.7. Sieve Analysis
Since the analysis of single tablets did not clarify the deviations between the LSM and HSM,
sieve analysis was chosen as an alternative method. A total weight of 25 g (the equivalent of
250 tablets) of LSM and HSM final powder mixtures along with the pure fibers were analyzed,
whose results are detailed in Table 5. Both LSM and HSM tablets are mainly (more than 90%) made up
of lactose and microcrystalline cellulose tableting materials, whose average particle sizes are 150 and
130 µm respectively.
Table 5. Sieve analysis results (the mixtures contain 5% ES material).
Sieve Size (µm) Pure ES Material (g) LSM Final Powder Mixture (g) HSM Final Powder Mixture (g)
355 13.80 0.22 0.02
180 1.61 5.02 5.41
90 1.03 9.22 9.35
sub 90 8.56 10.54 10.22
According to the weighed sieve fractions, HSM homogenization was able to decrease the 355 µm
portion by more than ten times compared to LSM mixing. This is crucial since the bulk of the pure
electrospun materials was recovered on this sieve and, more importantly for complete homogenization,
particle sizes should be as close to each other as possible to avoid segregation [55]. Based on these
results, the high-performance impeller and chopper blades present in the HSM can further reduce
the average particle sizes (due to high shear forces) of the fibrous materials, thus superior mixing of
materials can be realized. These aforementioned fractions were also evaluated by Raman spectroscopy
to look for traces of electrospun material. The spectra are shown in Figure 5.
Figure 5. Raman spectra pure ES (red) and sieved (black) material.
It is clear that the spectrum of the sieved material is almost identical to the spectrum of the
starting ES material ultimately proving that the API containing polymer was detected in the sieved
mixture. In the end, this resulted in higher inhomogeneity among LSM tablets compared to HSM
tablets. This outcome can be linked to Table 4 where the high SD and RSD values of the LSM tablets
validate these findings.
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Based on these results it is clear that a greater sample size was needed to be evaluated in
order to identify the causes of homogeneity differences observed between the mixing methods.
By implementing sieve analysis, the equivalent of 250 tablets could be screened, which enables
broader examination compared to single tablet Raman mapping.
This outcome proves that the high-shear mixer coupled with the direct compression technology
should be the first method of choice when proper homogenization of electrospun samples is required.
4. Conclusions
A low-dose, highly homogenous tablet formulation made from drug-loaded electrospun fibers
was demonstrated by applying HSM homogenization. Carvedilol, an antihypertensive drug was
used as the model API, while PVPVA64 was adopted as the matrix forming polymer. Electrospinning
was carried out by HSES with increased productivity, while the SNES technology was applied as the
reference. Homogenizations were made in plastic bags (LSM) and in an HSM, while tableting was
performed by a tablet rotary press. Tablet batches containing crystalline carvedilol served as reference.
Sieve analysis was used to study the particle size distribution in the final LSM and HSM powder
mixtures. API content and homogeneity were measured by UV-Vis spectrometry, while the latter was
also studied by Raman mapping.
HSM homogenization seems to be the preferred method of choice for preparing highly
homogenous tablets containing electrospun NASDs. Their RSD values were much lower than their
LSM counterparts. It is encouraging that this was achievable, despite setting a low API dose (50 µg) for
the tablets. The technology can be scaled up easily, which could be truly beneficial for both academic
researchers at universities and pharmaceutical technologists in the industry.
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